Search

Ulimorelin

Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility … of the GI tract is severely impaired.

VB2-011

VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. … This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).

Betaxolol

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

Dichloralphenazone

It is a US Schedule IV drug and its clinical use is limited. … Dichloralphenazone is a sedative composed of chloral hydrate and phenazone.

ZD4407

It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

Mimosine

Mimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.

PB127

Aranidipine

[A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.

Nedocromil

A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.

Polaprezinc

Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856].